Yichang Dongyangguang Yangtze River Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical is a leading Chinese pharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic products. The company holds a dominant position in the Chinese anti-influenza market with its flagship product, Kewei (Oseltamivir phosphate), which is available in both capsule and granule forms. Beyond anti-virals, HEC Pharm has established a robust portfolio in endocrine and metabolic diseases, particularly through its insulin series and SGLT2 inhibitors. As a subsidiary of the HEC Group, the company leverages extensive manufacturing infrastructure and a nationwide distribution network in China. It is listed on the Hong Kong Stock Exchange and continues to transition from a generics-focused business toward innovative drug development.